Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis
Main Article Content
Keywords
psoriasis, tildrakizumab
Abstract
Abstract not available.
Disclosures: Study sponsored by SUN PHARMA.
Copyright SKIN 2018